Biomedicines—Moving Biologic Agents into Approved Treatment Options
ExcerptThe development of biologic agents for therapeutic purposes, or biomedicines, has seen an active area of research both at the bench and in clinical trials. There is mounting evidence that biologic products can provide effective therapy for diseases that have been unresponsive to traditional pharmacologic approaches. Monoclonal antibody therapy for cancer and rheumatologic diseases has become a well accepted part of disease treatment plans. Gene therapy products have been approved in China and Europe. Bioengineering of new agents capitalizing on microRNA biology, nanoparticle technology, stem cell biology, and an increasing understanding of immunology predict a rich future for product development. [...] View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Cornetta, K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines 2013, 1, 1-2.
Cornetta K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines. 2013; 1(1):1-2.Chicago/Turabian Style
Cornetta, Kenneth. 2013. "Biomedicines—Moving Biologic Agents into Approved Treatment Options." Biomedicines 1, no. 1: 1-2.